Jaguar Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Health, Inc. on March 18, 2019. The filing details the entry into material definitive agreements involving the issuance of promissory notes to selected accredited investors. The company is classified as an emerging growth company.
Key Financial Metrics and Transaction Details
- Debt Issuance: The Company intends to issue up to $5.5 million in aggregate principal amount of promissory notes.
- Initial Closing: As of March 21, 2019, $800,000 in notes were issued, with proceeds paid to the Company.
- Interest Rate: Notes bear interest at 12% per annum.
- Maturity Date: July 18, 2019.
- Default Interest: In the event of default, interest accrues at 1.5% per month (18% annual).
- Use of Proceeds: Working capital and general corporate purposes.
- Liquidity Covenant: The Company must use 100% of net outside investments (excluding product sales) for note repayment.
Material Changes and Transaction Structure
The filing discloses a new financing arrangement not present in prior periods. The notes are structured in two types:
- 125% Coverage Notes: Subject to a mandatory exchange provision into common stock upon a public offering. Holders receive warrants to purchase shares equal to 125% of the principal amount.
- 75% Coverage Notes: Not subject to mandatory exchange. Holders receive warrants to purchase shares equal to 75% of the principal amount.
- Exchange Cap: Issuance of exchange shares and warrant shares is capped at 19.99% of total outstanding common stock unless shareholder approval is obtained.
- Dividend Restriction: The Company is restricted from paying dividends or making distributions on capital stock without investor consent.
Outlook, Risks, and Contingencies
The transaction includes a "put" option for Sagard Capital Partners, L.P., allowing them to purchase all or any portion of a note within 5 business days of notice. The Company has agreed to file a registration statement for the resale of warrant and exchange shares within 60 days of the maturity date and use reasonable best efforts to have it declared effective within 180 days. The filing does not provide specific revenue, profit, or cash flow metrics for the period, as this is a transactional report rather than a periodic financial statement.
Key Facts for Investor Verification
- Verify the total amount of notes issued beyond the initial $800,000 to determine if the full $5.5 million target was reached.
- Confirm the Company's ability to consummate a public offering by the July 18, 2019 maturity date to trigger the mandatory exchange of 125% Coverage Notes.
- Assess the dilution impact of the 19.99% exchange cap and the warrant exercise prices relative to the current market price.
- Review the Company's cash position to ensure compliance with the covenant requiring 100% of outside investment proceeds to be used for note repayment.
- Monitor the status of the registration statement filing required within 60 days of the maturity date.